Cannabis Import Requests in Brazil Have Grown 2400% Since 2015

Requests to import cannabis derivatives in Brazil have increased by more than 2400%, from 850 in 2015 to more than 35,000 in 2021, data from Anvisa – the National Health Surveillance Agency – reveal. In 2022, until the beginning of October, 58,245 requests for the importation of cannabis-derived products for therapeutic purposes have already been processed in Brazil, which confirms that medical cannabis in Brazil is booming.

Read more about the increase of cannabis imports in Brazil and find other important news in the cannabis sector with the Hemp.im mobile app. The application organizes what’s happening in the cannabis world to help you learn more about the stories that matter to you. Stay informed with the latest hemp news and get the important information in one application.

Why cannabis imports increased in Brazil

Applications for the importation of cannabis derivatives for therapeutic purposes are constantly increasing in Brazil, showing an average annual growth rate of around 400%, figures that could expand even further by the end of this year. If in 2015 there were 850 import requests, that number has skyrocketed to 35,416 in just 6 years. The recent election of Lula da Silva as the new president of Brazil now brings new hope for the industry, because it could represent advances in the regulation of cannabis in Brazil, something totally unthinkable for the previous government of Jair Bolsonaro.

Lula did not come out clearly in favor of legalization, but neither did he say he was against it, referring this decision to instances other than the government: “This is not an issue that the government has to deal with. This is a question that either the National Congress will deal with, or the Supreme Court will take care of it,” he told the Flow Podcast.

For its part, Brazilian civil society has been extremely active, having even overturned a resolution by the CFM – Federal Council of Medicine, which intended to limit the use and prescription of medical cannabis in the country to cannabidiol only.

In contradiction with Anvisa itself, which had published in October 2021 a list of cannabis-derived products approved for importation, the CFM received fierce criticism from several Brazilian quarters and ended up revoking the Resolution days after its publication.

Anvisa approved in 2021 the importation of 249 cannabis derivatives into Brazil, of which five with THC and 244 with CBD (cannabidiol). The authorized products followed a new resolution, with simpler rules for individual importation by Brazilian patients, but Anvisa clarified at the time that it “did not evaluate the efficacy, quality, or safety of the products,” referring to the legislation of the countries of origin.

__

(Featured image by Kindel Media via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in CANNA REPORTER, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.